MAPT and Alzheimer disease: Despite the surge in research on plasma AD biomarkers of amyloid (Aβ40 and Aβ42) and neuronal degeneration (t tau and NfL), there remain significant gaps in our understanding of the basic functioning of these biomarkers and the factors that may influence their levels.